Please activate JavaScript!
Please install Adobe Flash Player, click here for download
ePaper created 2016-09-22, 10:58:51 | version 1.38.0
news 2 25th EAO Annual Scientific Meeting According to a new series of re- ports on the European dental im- plants, final abutments and com- puter guided surgery market, over the past five years, the dental im- plant fixture market in Europe has experienced higher demand due to the recovering economy. Patients who held off dental implant proce- dures during the economic recession are now generating demand within the market. In countries such as Spain, the effect was lagging and therefore demand for dental im- plants has been substantial in more recent years. The dental implant fix- ture market in the UK has demon- strated the highest level of growth relative to the other countries in the region due to economic recovery and low market penetration. Market penetration levels for dental implants vary significantly across the European market. Coun- tries such as Italy, Spain, Switzer- land, Germany, Benelux and Scandi- navia represent more highly pene- trated dental implant markets. On the other hand, France and the UK are far less penetrated and bear a greater pool of potential dental im- plant patients. It is expected that the French market for dental implants will begin to demonstrate more sig- nificant growth throughout the fore- cast period. “The European market is demon- strating a shift towards price-cutting discounts and value implant options,” explains Dr Kamran Zamanian, CEO of iData. “This, in turn, has largely de- pressed prices and handicapped the overall market value growth. The growing prevalence and popularity of discounted products have there- fore led to premium implant compa- nies levying larger discounts on their products.” Governments in Sweden, the Netherlands, Germany and Switzer- land offer some reimbursement for dental implant procedures. However, even with reimbursement, costs asso- ciated with implant procedures tend to be higher than alternative treat- ments. Partially as a result of these policies, Sweden and Switzerland have some of the highest per capita implant rates in the world. Addition- ally, the Netherlands has experi- enced incredibly rapid dental im- plant market growth since the intro- duction of its reimbursement policy in 2005. Most private health and den- tal insurance policies do not cover dental implants, but a few high-end policies do. However, only a small percentage of the population in Eu- rope is covered by such policies. The dental implant market is not a commodity market. Large, estab- lished companies have built up strong brand recognition and a certain de- gree of customer loyalty. This, com- bined with the fact that the cost of the implant is only a small part of the cost of the procedure, allows established companies to price their products at a high premium relative to smaller com- panies who do not have the same level of brand recognition. Straumann holds the leading po- sition in the dental implant market in Germany, Spain, Benelux, Austria and Switzerland. Straumann benefits from a relatively stable customer base, even in regions like Germany, where a high level of competitive pressure exists from local value and discount implant companies. In Ger- many for example, the largest con- tributing factor to growth in recent years has been the company’s cam- paign which offered a free upgrade from titanium implants to the new higher strength Roxolid material. Ad- ditionally, Straumann lowered the price of their basic titanium SLA im- plant to compete within the value segment. The company also invested in a number of value and discount brands that cater to the European market including: Neodent, Biodenta, Medentika and MegaGen. In France, Nobel Biocare contin- ued to hold the market leading posi- tion despite sluggish growth in the re- gion. Overall, Nobel Biocare held the second leading position within the dental implant market in Europe. DENTSPLY Implants hold the third leading position in Europe. The pro- gression of DENTSPLY’s market share is a primary result of their acquisi- tion of Astra Tech in August 2011. In the UK, DENTSPLY emerged as the market leader, closely followed by Straumann. Other competitors in the European dental implant market in- clude BIOMET 3i, CAMLOG, Sweden & Martina, Zimmer Dental, MIS Im- plant, BEGO, Global D, Klockner, Bio- Horizons, Implant Direct, BTI, Phibo, MegaGen, Bredent, Osstem, Antho- gyr, Medentis, and Southern Implants among others. Information in this article was pro- vided by iData Research (www.idata- research.com). Straumann, Nobel Biocare, DENTSPLY take advantage of growing dental implant demand in Europe UK dental implant fixture market shows highest level of growth © GagliardiImages/Shutterstock.com Investigating patients’ knowledge and perceptions regarding implant therapy, a Chinese study has found that an alarming number of partici- pants had inaccurate and unrealistic expectations about dental implants. Moreover, the study determined that only 18 per cent felt confident about the information they had about the treatment. In the study, the researchers inves- tigated preoperative information lev- els, perceptions and expectations re- garding implant therapy via a ques- tionnaire. Responses from 277 patients were obtained during 2014 and 2015 in three different locations in China (Hong Kong, Sichuan and Jiangsu). The analyses established that about one-third of the participants had mistakenassumptionsaboutdentalim- plants. According to the researchers, common misconceptions were that dental implants require less care than natural dentition, implant treatment is appropriate for all patients with miss- ing teeth, dental implants last longer than natural dentition, and there are no risks or complications with implant treatment. Overall, younger respondents (< 45) and those with higher education (bachelor’s and postgraduate degrees) tended to have more realistic percep- tions and lower expectations of the treatment outcome. When asked about their level of knowledge, 63 per cent of the partici- pants said that they were generally in- formed about implants, but only 18 per cent felt confident about the informa- tion they had. New research has linked antide- pressants to dental implant failure. The pilot study conducted at the Uni- versity at Buffalo found that antide- pressants, one of the most prescribed drugs in the US to treat anxiety, pain and other disorders, could affect the regulation of bone metabolism, a cru- cial factor for the healing process and implant success. In the study, the researchers ana- lysed data from the medical charts of the university’s dental clinic patients in 2014. They found that of the few patients who experienced implant failures, 33 percent used antidepres- sants. For patients who did not expe- rience failures, only 11 per cent took the drug. Overall, the analysis showed that use of antidepressants increased the odds of implant failure fourfold. Each year of antidepressant use doubled the odds of failure, the researchers stated. Therefore, they advise patients using antidepres- sants to consult with their physician about the drug’s side effects and al- ternative methods of managing de- pression, anxiety or pain. According to figures from the Centers for Disease Control and Pre- vention, 11 per cent of Americans aged 12 and over took antidepressant medication in 2011. Antidepressants were the third most common pre- scription drug taken by Americans of all ages in 2005–2008 and the most frequently used by persons aged 18– 44. From the period 1988–1994 to the period 2005–2008, the rate of antide- pressant use in the US among all age groups increased by nearly 400 per cent. Antidepressant use has been as- sociated with a number of side ef- fects, including osteoporosis, aka- thisia, bruxism and dry mouth, all of which affect the implant healing pro- cess and are of concern for dentists with regard to oral and bone health, the investigators noted. Currently, the researchers are planning to validate their initial find- ings in a larger-scale study. Fundamental misconceptions about dental implants Antidepressant use could increase implant failure risk Editorial/Administrative Office Dental Tribune International GmbH Holbeinstraße 29 04229 Leipzig, Germany Phone: +49 341 48474-302 Fax: +49 341 48474-173 Internet: www.dti-publishing.com www.dental-tribune.com Publisher Torsten Oemus Director of Finance and Controlling Dan Wunderlich Managing Editor Daniel Zimmermann Editorial Assistant Anne Faulmann Business Development Claudia Salwiczek-Majonek Product Manager Antje Kahnt Production Executive Gernot Meyer Production Matthias Abicht today will appear at the 25th EAO Annual Scientific Meeting in Paris, 29 September–1 October, 2016. The magazine and all articles and illustrations therein are protected by cop- yright. Any utilisation without prior consent from the editor or publisher is inadmissible and liable to prosecution. No re- sponsibility shall be assumed for information published about associations, companies and commercial markets. General terms and conditions apply, legal venue is Leipzig, Germany. about the publisher © Photographee.eu/Shutterstock.com Phone: +4934148474-302 Fax: +4934148474-173